INSR Peptide
€100.00
In stock
SKU
350472
Protein Family: Cellular Antigens, Enzymes, Protein Kinases, Receptors and Channels
Pathway and Disease: Cell Communication, Endocrine System, Metabolic Disorders, Neurodegenerative Disorders
Alternate Names: Insulin receptor; CD220 antigen; IR; INSR
Accession No.: P06213, NP_000199
Description:
INSR binds insulin and has a tyrosine protein kinase activity. The short isoform has a higher affinity for insulin. The receptor mediates the metabolic functions of insulin. The receptor binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Defects in INSR are the cause of insulin resistance.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1952.2 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200110 is selected from a sequence within the N-term region of human INSR. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C87H138N24O25S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cell Communication, Endocrine System, Metabolic Disorders, Neurodegenerative Disorders
Alternate Names: Insulin receptor; CD220 antigen; IR; INSR
Accession No.: P06213, NP_000199
Description:
INSR binds insulin and has a tyrosine protein kinase activity. The short isoform has a higher affinity for insulin. The receptor mediates the metabolic functions of insulin. The receptor binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Defects in INSR are the cause of insulin resistance.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1952.2 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200110 is selected from a sequence within the N-term region of human INSR. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C87H138N24O25S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review